Hi Wilius, the company has solid technology, there have been...

Hi Wilius, the company has solid technology, there have been delays that management have overcome, The Companies announcements seem to fall flat, ie other Biotechs gain mileage in the form of awareness that generates demand and an increase in the SP.
DXB have released the same announcements as other Biotechs but didn't gain the wider markets attention.. eg

1. DMX-200 Phase 2a Data Presentation
   16/08/17 08:25
   336.45KB
   N
   14854
2. DXB
   Board Restructure and Incentive Package for CEO
   01/08/17 08:20
   334.47KB
   N
   225
3. DXB
   Appendix 4C - quarterly
   31/07/17 08:17
   416.41KB
   Y
   208
4. DXB
   Phase 2a Trial Result Release Interview Video Recording
   17/07/17 08:21
   52.3KB
   N
   39275
5. DXB
   Phase 2a Trial Result Release Conference Call Recording
   13/07/17 18:23
   45.97KB
   N
   368
6. DXB
   DMX-200 Phase 2a Trial - Investor Presentation
   12/07/17 09:50
   2.6MB
   N
   3887
7. DXB
   Positive Results from Phase 2a Trial of DMX-200T

These are generally large catalyst moments in a Biotechs Journey, that reflect a solid increase in value that should be reflected in the SP,, even if it wasnt recognised early the value would become more apparent as the announcements especially PhaseII de-risks a huge part of the Venture. if you look at he corresponding SP through out the above dates the SP barely clipped over 1c. the re-rate was designed in part to highlight the company and its value, 21/22c.
So either there is Value here and that has been building but not reflected in the current SP, because DXB have been poor in broadcasting a clear definitive message in which case you can expect a rapid increase to be corrected, or the marketing material and announcements being made by DXB are not stating clearly enough the companies Position and Investment Opportunity upside to Investors..
You would have noted the incredible increase in the standard of Marketing and PR material being produced by even the Novice Biotechs , I believe this new level of clear concise documentation is attracting the investment dollars,,, anything that isn't easily digested by the common investor (non medical Background) with a clear investment proposition is being passed over for investment funds...
I don't agree with Stormer all the time , especially any personal attacks, but he does have some valid points. Mainly is management doing the very best for Shareholders,,because the SP is seriously not reflecting that at present...